Gretchen G. Kimmick

Hematology | Oncology

20 Duke Medicine Cir
Durham, NC 27710

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 114 publications

Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 26, 2026

Adjuvant chemotherapy for breast cancer: are all dose reductions inappropriate?

Adjuvant chemotherapy for breast cancer: are all dose reductions inappropriate?

Journal: Journal of the National Cancer Institute

Published: March 25, 2026

Social wellbeing in older breast cancer survivors taking adjuvant endocrine therapy: impacts of self-efficacy for symptom management and pain.

Social wellbeing in older breast cancer survivors taking adjuvant endocrine therapy: impacts of self-efficacy for symptom management and pain.

Journal: Frontiers in aging

Published: March 16, 2026

Beyond efficacy: CDK4/6 inhibitors in metastatic breast cancer.

Beyond efficacy: CDK4/6 inhibitors in metastatic breast cancer.

Journal: The Lancet. Oncology

Published: March 04, 2026

Characterizing Alcohol Use and Expectancies for Alcohol Analgesia Among Breast Cancer Survivors With Arthralgia.

Characterizing Alcohol Use and Expectancies for Alcohol Analgesia Among Breast Cancer Survivors With Arthralgia.

Journal: Psycho-oncology

Published: February 24, 2026

TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.

TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 28, 2026

Clinical and Demographic Characteristics of Patients With Long-Term Disease Control With First-Line Endocrine Therapy Alone for Hormone Receptor Positive, HER2 Negative, Metastatic Breast Cancer.

Clinical and Demographic Characteristics of Patients With Long-Term Disease Control With First-Line Endocrine Therapy Alone for Hormone Receptor Positive, HER2 Negative, Metastatic Breast Cancer.

Journal: Clinical breast cancer

Published: January 14, 2026

Examining the Interrelationships of Lymphedema with Pain, Physical Function, and Demographic and Medical Variables in Women with Breast Cancer and Pain.

Examining the Interrelationships of Lymphedema with Pain, Physical Function, and Demographic and Medical Variables in Women with Breast Cancer and Pain.

Journal: Clinical breast cancer

Published: May 02, 2025

Adjuvant Radiation vs Endocrine Therapy After Lumpectomy for Early-Stage Breast Cancer in Older Women: Analysis of Real-World Survival Outcomes.

Adjuvant Radiation vs Endocrine Therapy After Lumpectomy for Early-Stage Breast Cancer in Older Women: Analysis of Real-World Survival Outcomes.

Journal: Annals of surgical oncology

Published: March 04, 2025

The Cost-Effectiveness of CDK4/6 Inhibitors in Treating HR+/HER2- Metastatic Breast Cancer Patients in the USA: When Non-medication Expenses are Considered.

The Cost-Effectiveness of CDK4/6 Inhibitors in Treating HR+/HER2- Metastatic Breast Cancer Patients in the USA: When Non-medication Expenses are Considered.

Journal: Clinical drug investigation

Published: December 08, 2024

Receipt of guideline-concordant local and chemotherapy-based systemic therapy for patients with triple-negative breast cancer: 10-year survival outcomes in a multi-state population-based analysis.

Receipt of guideline-concordant local and chemotherapy-based systemic therapy for patients with triple-negative breast cancer: 10-year survival outcomes in a multi-state population-based analysis.

Journal: Cancer

Published: October 18, 2024

Disparities in treatment delays among metastatic breast cancer patients: insights from nationwide electronic health records, 2011-2022.

Disparities in treatment delays among metastatic breast cancer patients: insights from nationwide electronic health records, 2011-2022.

Journal: Breast cancer research and treatment

Published: September 01, 2024

Showing 1-12 of 114

Last Updated: 09/26/2026